 Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
| Descriptor ID |
D019008
|
| MeSH Number(s) |
G07.690.773.984.395
|
| Concept/Terms |
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Resistance, Antineoplastic Agent
- Resistance, Antineoplastic Drug
- Drug Resistance, Antineoplastic
- Neoplasm Drug Resistance
- Antineoplastic Agent Resistance
- Antineoplastic Drug Resistance
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 | | 1998 | 0 | 3 | 3 | | 2000 | 1 | 2 | 3 | | 2001 | 0 | 3 | 3 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 4 | 4 | | 2004 | 2 | 1 | 3 | | 2005 | 3 | 4 | 7 | | 2006 | 0 | 4 | 4 | | 2007 | 5 | 11 | 16 | | 2008 | 4 | 4 | 8 | | 2009 | 6 | 7 | 13 | | 2010 | 10 | 13 | 23 | | 2011 | 5 | 12 | 17 | | 2012 | 6 | 15 | 21 | | 2013 | 10 | 18 | 28 | | 2014 | 11 | 12 | 23 | | 2015 | 13 | 16 | 29 | | 2016 | 15 | 31 | 46 | | 2017 | 16 | 21 | 37 | | 2018 | 16 | 27 | 43 | | 2019 | 19 | 12 | 31 | | 2020 | 13 | 12 | 25 | | 2021 | 18 | 11 | 29 | | 2022 | 4 | 7 | 11 | | 2023 | 1 | 8 | 9 | | 2024 | 17 | 15 | 32 | | 2025 | 18 | 22 | 40 | | 2026 | 10 | 7 | 17 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
Cheng K, Nie H, Zhou W, Guo D, Liao L, Zhang X, Wang C, Zielinski RJ, Gavade JN, Sriramkumar S, Fang Y, Xia S, Wu S, Tang HY, Kossenkov AV, Qi Y, Liu J, Le K, Gruber D, Soth MJ, Post MD, Sood AK, Flückiger-Mangual S, Yap TA, Bitler BG, Zhang R. Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance. Cancer Res. 2026 Oct 02; 86(19):4934-4954.
-
Wang ES, Erba H, Zeidan AM, Roboz GJ, Altman JK, Advani AS, Lin TL, Strickland SA, Juckett MB, Pratz KW, Mangan JK, McMahon CM, Alsfeld LC, Balasubramanian SK, Guru Murthy GS, Rotta M, Palmisiano ND, McCloskey J, Saliba AN, Khawandanah M, Madanat YF, Naqvi K, Qasrawi AH, Schiller GJ, Badar T, Gojo I, Yaghmour G, Osman D, Zhang H, Tian Y, Soifer HS, Riches M, Corum D, Leoni M, Fathi AT, Issa GC. Ziftomenib with venetoclax and azacitidine for relapsed/refractory NPM1-mutated acute myeloid leukemia. Blood. 2026 Oct 01; 148(14):1775-1788.
-
Campbell KM, Chen DG, Bustami ZE, Naser Al Deen N, Medina E, Gonzalez CR, Maxey J, Thompson MA, Samorodnitsky S, Kuklinski LF, Perez Garcilazo I, Baselga-Carretero I, Vega-Crespo A, Chen JM, Elumalai R, Visitacion M, Schiemann R, Padron L, Chang C, Zelin AE, Chelluri SS, Boffo S, Kendra KL, Chmielowski B, Truong TG, Khushalani NI, Collichio F, Ikeguchi AP, Victor AI, Margolin KA, Johnson DB, Chen Y, Sosman JA, Patel SP, Hu-Lieskovan S, Moon J, Wells DK, Spencer CN, Bellasea S, Vanderwalde AM, Wu MC, Scumpia PO, Ribas A. Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti-CTLA-4 in Melanoma with Primary Resistance to Anti-PD-1. Cancer Discov. 2026 Sep 01; 16(9):1801-1818.
-
Keller AL, Dennis KA, Ohlstrom DJ, Parzych SE, Walker ZJ, Novak AJ, Pham-Danis C, Medha TN, Rahkola JT, Boorgula MP, Kohler ME, Sherbenou DW. Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype. Cancer Immunol Res. 2026 Aug 04; 14(8):1307-1321.
-
Sokol E, Naranjo A, Chen L, Mody R, DuBois SG, Bagatell R, Pinto N. Long-Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2026 Sep; 73(9):e70504.
-
Garcia C, Lyons KU, Contreras JG, Liu T, Donnelly AJ, Novak AJ, Argabright A, Anderson C, Grier A, Smith S, Michlin J, Olusoji J, Mikeska RG, Zhou X, Geng H, Rahkola JT, Patel HN, Jacot JG, Müschen M, D'Alessandro A, Dick JE, Iacobucci I, Mullighan CG, Reisz JA, Phang T, Eric Kohler M, Witkowski MT. FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia. Leukemia. 2026 Aug; 40(8):1763-1777.
-
De León AG, An JJ, Gourgioti G, Xie Y, Zhong J, Wu EQ, Ariza JG, Cheng LJ. Treatment landscape, outcomes, and healthcare resource utilization in FLT3+ relapsed/refractory acute myeloid leukemia in Mexico. Cancer Treat Res Commun. 2026; 48:101229.
-
Figueroa V, Coianis MI, Sahores A, Pataccini G, Abba MC, Elía A, May M, Vanzulli SI, Martínez Vázquez P, Burruchaga J, Torres F, Sartorius CA, Lanari C, Lamb CA. Nuclear FGF2, androgen receptor and Wnt pathway activation define a targetable subset of antiprogestin-resistant luminal breast cancer. Br J Cancer. 2026 Jun; 134(11):1671-1682.
-
Liang J, Ong C, Heslop K, Guan J, Kameswaran V, Daniel B, Shi M, Liang Y, Giltnane JM, Aimi J, Chang CW, Gates MR, Eng-Wong J, Perez-Moreno P, Jhaveri KL, Turner NC, Lim E, Metcalfe C, Moore HM. Loss of luminal lineage drives resistance to next-generation ERa antagonists in pretreated ER+ HER2- locally-advanced or metastatic breast cancer. Nat Commun. 2026 Apr 01; 17(1).
-
Hinz TK, Le AT, Doan T, Ast A, Jaramillo S, Avila JT, Skhisov D, Haines S, Navarro AC, Patil T, Nemenoff RA, Heasley LE. Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma. Cancer Lett. 2026 Jun 28; 648:218467.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|